KEYONIQ
Investor relations

Building the next generation of preventive health.

A Swiss HealthTech platform moving from validated science toward commercialisation. Scientifically grounded, clinically relevant, designed to scale.

Health intelligence→ Clinical intelligence→ Preventive care
The opportunity

Chronic disease is the largest cost in Swiss healthcare. Prevention gets 1.5%.

Non-communicable diseases cause most deaths worldwide and most of Switzerland’s health spending, yet prevention receives half the OECD average. Routine blood tests are already taken every day. KEYONIQ makes them count.

2.7M
people in Switzerland aged 15+ live with at least one of the five most common NCDs
CHF 65.7bn
direct medical costs of NCDs in Switzerland, 2022
72%
share of NCDs in total Swiss healthcare costs
1.5%
of Swiss health spending goes to prevention (2024), vs. 3% OECD average (2023)

Sources: BAG / FOPH, Swiss Health Survey and direct healthcare costs, 2022; OECD, Health at a Glance 2025; BAG & Obsan, MonAM – Präventionsausgaben 2024. Globally, NCDs caused 43 million deaths in 2021 (WHO, 2025).

Investment pillars

Six pillars. One capital-efficient platform.

Each pillar earns on its own. Together they form a continuous care loop and a model designed for healthcare distribution, first in Switzerland, then in the EU and internationally.

Pillar 01
Health Intelligence
SevenAge™
Biological age from six routine biomarkers: a low-cost, scalable gateway into personalised prevention.
Per-test & API revenueLaboratory partnershipsPreventive health packages
Pillar 02Core asset
Clinical Intelligence
InsightQore™ Nova
The core technology asset: evidence-based decision support that turns complex health data into physician-reviewed recommendations.
Enterprise SaaS licencesPer-physician & per-patient feesWhite-label licensing
Pillar 03
Preventive Health & Longevity Services
KEYONIQ Health Center
Direct care revenue, and the clinical implementation and validation engine for the whole portfolio.
Assessments & consultationsPersonalised programmesMemberships
Pillar 04
Continuous Health Engagement
InsightQore™ Nova Connect
A personal health companion between visits, driving adherence, outcomes and retention.
Recurring engagementLongitudinal dataHigher retention
Pillar 05
Platform & Partnerships
Technology & IP distribution
The multiplication layer: scaling through hospitals, clinics, labs, insurers and employers rather than new clinics.
Enterprise & SaaS licensingAPI & usage feesRevenue sharing
Pillar 06
Supplement Portfolio
Nutrition formulas
Clinic-dispensed formulas extending preventive programmes in Switzerland and partner networks.
B2B & B2C salesPartner distribution
The investment case

Making preventive health scalable and investable.

Differentiation

A feedback loop that compounds

Technology → clinical application → health trajectories → data → improved technology

01
Measure
SevenAge™ and laboratory biomarkers.
02
Interpret
InsightQore™ Nova clinical intelligence.
03
Act
Physician-led interventions and programmes.
04
Re-measure
SevenAge™ shows what changed; outcomes and physician feedback refine InsightQore™.
Traction

From validated science to clinical scale.

AchievedPlanned
2023
KEYONIQ Technologies founded in Baar, Switzerland.
Live
InsightQore™ Nexa deployed in clinical practice at Bumrungrad and VitalLife.
2025
SevenAge™ published in Scientific Reports.
Q1 2026
SevenAge™ commercially deployed.
Aug 2026
ISO 13485 certification for InsightQore™ Nova quality management.
Q4 2026
Health Center soft opening; InsightQore™ Nova in final-stage Class IIa certification.
2027
Clinic ramp-up and InsightQore™ Nova roll-out.
The entry point

SevenAge™ is a gateway, not just a test.

An inexpensive assessment on routine blood values opens a scalable funnel towards deeper preventive-health services. Its API can serve millions of assessments at very low marginal cost.

~2,500
SevenAge™ tests per month on average, already running at our client clinics.
01Revenue generatorTransactional from day one: tests × revenue per test.
02Lead generatorTurns a routine check-up into a first step towards care.
03Platform entry pointLeads partners and patients into InsightQore™ Nova.
04Data generatorLongitudinal measurements that improve every model.
Go-to-market

Focused B2B and B2B2C commercialisation

Now
Initial channels
Hospital and clinic partners, building on the Bumrungrad and VitalLife relationship.
Next
Expansion channels
Laboratories, international healthcare partners, employers and insurers.
Journey
Customer journey
Entry via SevenAge™; deeper clinical intelligence and preventive programmes.
Ownership & governance

Institutional foundation

Bumrungrad International Hospital
Healthcare heritage
KEYONIQ has its roots in Bumrungrad International Hospital, a leading healthcare institution in Southeast Asia, publicly listed since 1989.
Parent company support
Strong support providing stability, resources and long-term commitment.
Clinical expertise and trust
Access to clinical know-how and established medical credibility.

Request data-room access

The investor presentation, financial information and diligence materials are available to qualified parties under a non-disclosure agreement.

Request access

Let's shape the future of preventive health together.

Get in touch